



**COST Action 17104 (STRATAGEM) WG3 Meeting - International
Online Symposium on “New Therapeutic Tools Against
Preclinical Models of Multidrug Resistant Tumors”**

4th November 2020

ORGANISING COMMITTEE:

Helena Vasconcelos – WG3 Leader (Portugal)

Nuray Erin – WG3 Vice-Leader (Turkey)

Chiara Riganti –Chair (Italy)

Yordan Yordanov– Science Communications Manager (Bulgaria)

Dale Lawson – Grant Holder Manager (Italy)

SCIENTIFIC COMMITTEE:

Chiara Riganti –Chair (Italy)

Roberta Fruttero - Former Chair (Italy)

Javier de Las Rivas - Vice-Chair (Spain)

Thomas Mohr - WG1 Leader (Austria)

Catherine Passirani – WG2 Leader (France)

Helena Vasconcelos – WG3 Leader (Portugal)

Nuray Erin – WG3 Vice-Leader (Turkey)

Simona Saponara –WG4 Leader (Italy)

Milica Pesic – Short Term Scientific Missions (STSM) Coordinator (Serbia)

Yordan Yordanov– Science Communications Manager (Bulgaria)

Jitka Viktorova- Early Career Investigators (ECI) Coordinator (Czech Republic)



FINAL PROGRAM
(IN CENTRAL EUROPEAN TIMES)

9.30h Welcome

Chiara Riganti, Chair of STRATAGEM and Helena Vasconcelos, WG3 Leader

9,40h - 13,00h – MORNING SESSION

9,40h Keynote Lecture I

Moderator: Helena Vasconcelos, WG3 Leader

"Pancreatic cancer: why is it so hard to treat? Molecular mechanisms underlying resistance and new therapeutic strategies"

Elisa Giovannetti

Department of Medical Oncology, Amsterdam Universities Medical Centers, Cancer Center Amsterdam, The Netherlands; Cancer Pharmacology Lab, Fondazione Pisana per la Scienza, Pisa, Italy

10,30 – 11,50h – Selected Oral Presentations

Moderator: Nuray Erin, WG3 Vice-Leader

10,30h "Drug response prediction in CML: the value of microRNAs expression profile"

Raquel Alves, Ana Cristina Gonçalves, Joana Jorge, Paulo Freitas-Tavares, Bárbara Oliveiros, António Almeida, Ana Bela Sarmiento-Ribeiro

10,50h "Small nucleolar RNAs mediate doxorubicin resistance in osteosarcoma"

Martina Godel, Joanna Kopecka, Chiara Riganti



11,10h “Chitinase 3-like-1 and Fibronectin present on extracellular vesicles shed by human macrophages induce gemcitabine resistance in pancreatic cancer cells”

Cristina P.R. Xavier, Inês Castro, Hugo R. Caires, Dylan Ferreira, Bruno Cavadas, Luisa Pereira, Lúcio L. Santos, Maria J. Oliveira, M. Helena Vasconcelos

11,30h “Novel Acoustic Wave Programmed 3D Vascularised Cancer Model in Malignant Pleural Mesothelioma: a platform for drug screening”

Preeta Ananthanarayanan, Nicola DiMarzio, A. Geraldine Guex, Mauro Alini, Tiziano Serra, Chiara Riganti

11,50 Coffee-Break

12,00h-13,00h WG3 members meeting (for WG3 members)

Moderators: Helena Vasconcelos, WG3 Leader and Nuray Erin, WG3 Vice-Leader

13,00h - 14,00h Interval (Lunch Break)



14,00h – 18,00h – AFTERNOON SESSION

14,00h Keynote Lecture II

Moderator: Chiara Riganti, Chair of STRATAGEM

"The role of drug sequestration and physicochemical properties in drug uptake and resistance"

Godefridus J. Peters

Laboratory of Medical Oncology, Amsterdam UMC, location VUMC, Amsterdam, The Netherlands, and Department of Biochemistry, Medical University of Gdansk, Poland

14,50h– 16,10h – Selected Oral Presentations

Moderator: Helena Vasconcelos, WG3 Leader

14,50h "Urokinase-type Plasminogen Activator and Peroxiredoxin 2 in cancer cell exosomes may lead resistance to CXCR2 antagonists by release of CXCR2 ligands"

Nur Ogan, Nuray Erin

15,10h "MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor"

Chiara Riganti, Roberta Giampietro, Joanna Kopecka, Costanzo Costamagna, Francesca Serena Abatematteo, Marialessandra Contino and Carmen Abate

15,30h "Development and anticancer activity of hypoxia-activatable prodrugs of the tyrosine kinase inhibitor crizotinib"

H. Schueffl, B. Bielec, A. Terenzi, B. K. Keppler, C. R. Kowol and P. Heffeter

15,50h "Self-assembling nanoparticles encapsulating zoledronic acid overcome immune-resistance in human osteosarcoma"



Muhlis Akman, Dimas Carolina Belisario, Martina Godel, Virginia Campani, Maria Pia Patrizio, Lorena Scotti, Claudia Maria Hattinger, Giuseppe De Rosa, Massimo Donadelli, Massimo Serra, Joanna Kopecka, Chiara Riganti

16,10h Coffee-break

16,20h – 18,00h Speed-Talks of Poster Presentations

Moderators: Milica Pesic, Short Term Scientific Missions Coordinator and Jitka Viktorova, Early Career Investigators (ECI) Coordinator

16,20h “Gender and estrogens as key factors in the response to immunotherapy in non-small cell lung cancer”

Sofia La Vecchia, Dario Pasquale Anobile, Fabrizio Tabbò, Iris. C. Salaroglio, Joanna Kopecka, Luisella Righi, Giorgio Vittorio Scagliotti, Silvia Novello, Chiara Riganti

16,25h “Expression of Fibulin-4, LTBP and BMP-1 levels in human breast carcinoma samples as well as liver metastasis”

Nuray Erin, Ahmet Boduroğlu, Gülgün Erdoğan, Özlem Elpek

16,30h “Multidrug Resistant cells show different ability to release and capture EVs than their sensitive counterparts: effect of endocytic pathway regulation”

Diana Sousa, Raquel T. Lima, Vanessa Lopes-Rodrigues, Esperanza Gonzalez, Félix Royo, Juan M. Falcón-Pérez, M. Helena Vasconcelos

16,35h “Drug sequestration by Extracellular Vesicles: preliminary evidence for a role of P-glycoprotein in this process”

Diana Sousa, Rita Rebelo, Raquel T. Lima, Cristina P.R. Xavier, M. Helena Vasconcelos



16,40h "Inhibition of bone morphogenetic protein 1 activity decreases colony and spheroid formation in metastatic breast carcinoma cells"

Esra Nizam, Nuray Erin

16,45h "Elucidating mechanisms of resistance against the anticancer thiosemicarbazone COTI-2 by structural modifications and metal complex formation"

Sonja Hager, Julia H. Bormio Nunes, Marlene Mathuber, Vivien Pósa, Éva A. Enyedy, Alessia Stefanelli, Walter Berger, Bernhard K. Keppler², Christian R. Kowol, Petra Heffeter

16,50h "Cell speed as phenotypic signature in drug discovery"

Mónica Suárez Korsnes, Reinert Korsnes

16,55h "Everolimus - a mTOR inhibitor as a new drug for CML treatment"

Raquel Alves, Ana Cristina Gonçalves, Joana Jorge, Paulo Freitas-Tavares, Amélia Pereira, José Nascimento-Costa, António Almeida, Ana Bela Sarmiento-Ribeiro

17,00h "Development of New Trastuzumab-Chelating Agent Complexes for Breast Cancer Treatment"

Emre Ozgenc, Evren Gundogdu, Zeynep Burak

17,05h "Active principles obtained from plants of Argentina as new therapeutic tools against multi-drug resistant tumors"

Jerónimo Laiolo¹, M. Florencia García Manzano¹, M. Belén Joray¹, Tihomir Tomašić², Mariano Vera, Danijel Kikelj, M. Cecilia Carpinella

17,10h "Novel class of P-glycoprotein inhibitors from Plectranthus spp."

Vera M. S. Isca, Jaime A. S. Coelho, Carlos M. Monteiro, Epole Ntungwe, Eva María Dominguez-Martín, Jelena Dinic, Ana María Díaz-Lanza, Nuno R. Candeias, Carlos A. M. Afonso, Milica Pesic, Patrícia Rijo



17,15h “Overcoming ABC transporters-mediated MDR in cancer: alkylated indole alkaloid derivatives as ABCB1 inhibitors “

David S. P. Cardoso, Annamária Kincses, Márta Nové, Gabriella Spengler, Silva Mulhovo, João Aires-de-Sousa, Daniel J. V. A. dos Santos, and Maria-José U. Ferreira

17,20h “Cancer and Bacterial Multidrug Resistance Modulation By Natural and Semi-synthetic Flavonolignans”

Katerina Rehorova, Simona Dobiasova, Lan Hoang, Tomas Macek, Vladimir Kren, Jitka Viktorova

17,25h “Resistance modulating activity of selenoesters in bacteria”

Nikoletta Szemerédi, Annamária Kincses, Katerina Rehorova, Jitka Viktorova, Enrique Domínguez-Álvarez and Gabriella Spengler

17,30h “TRPV1 modulators synergistically enhances anti-proliferative effects of Amitriptyline on metastatic breast carcinoma cells”

Seren Haksever, Nuray Erin

17,35h “A novel small-molecule compound targeting Hakai for anticancer therapy”

Andrea Rodríguez-Alonso, Alba Casas-País, Olaia Martínez-Iglesias, Daniel Roca-Lema, Ángel Concha, Gabriela Romay, Álvaro Cortés, Federico Gago, and Angélica Figueroa

17,40h “Inhibitors of tumor cell growth and P-glycoprotein as potential anti MDR agents”

Andreia Palmeira, M. Helena Vasconcelos, Emília Sousa, Madalena M. M. Pinto



17,45h “Efficacy and molecular mechanism of action of MDR-reversal stony brook taxanes in resistant in vitro and in vivo models of ovarian cancer cells”

Vaclavikova R. , Koucká K., Ehrlichová M., Šeborová K., Holý P., Ojima I., Kristensen V.N., Luders T. and Souček P.

17,50h “Efflux pump inhibition by symmetric selenoesters on colon adenocarcinoma cells”

Bálint Rác, Annamária Kincses, Miguel Benito-Lama, Ana González-Prádena, Enrique Domínguez-Álvarez and Gabriella Spengler

17,55h “Novel TrxR1 inhibitors induce oxidative stress and sensitize human multidrug resistant glioblastoma cells to chemotherapy”

Ana Podolski-Renić, Mirna Jovanović, Miodrag Dragoj, Jelena Dinić, Sofija Jovanović Stojanov, Milica Pešić

18,00h Prizes for best presentations (to be announced on the Stratagem website) and

Closing remarks

Chiara Riganti, Chair of STRATAGEM and Helena Vasconcelos, WG3 Leader

18,10h End of Day



**COST Action 17104 (STRATAGEM) WG3 Meeting - International
Online Symposium on “New Therapeutic Tools Against
Preclinical Models of Multidrug Resistant Tumors”**

4th November 2020

**Prizes (Certificates) for 2 “Best Selected Oral Presentations” and 3 “Best
Speed-Talks/Posters” will be announced on the STRATAGEM webpage**

PRIZES SELECTION COMMITTEE:

Thomas Mohr - WG1 Leader (Austria)

Catherine Passirani – WG2 Leader (France)

Simona Saponara –WG4 Leader (Italy)

Milica Pesic – Short Term Scientific Missions (STSM) Coordinator (Serbia)

Jitka Viktorova- Early Career Investigators (ECI) Coordinator (Czech Republic)

Yordan Yordanov– Science Communications Manager (Bulgaria)